CONTACT US
News and Stories About Precision Promise
Precision Promise Update
We wanted to share an update about PanCAN Precision Promise℠, the first adaptive clinical trial for pancreatic cancer and PanCAN’s […]
READ MORE
PanCAN Initiatives Highlighted at Gastrointestinal Cancers Conference
The 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium took place Jan. 18-20 in San Francisco, bringing […]
READ MORE
PanCAN Announces a Strategic Alliance with GCAR for Precision Promise
Happy New Year! I am excited to share with you an update about Precision Promise, our adaptive clinical trial platform […]
READ MORE
The Pancreatic Cancer Action Network and the Global Coalition for Adaptive Research Forge a Powerful Alliance to Accelerate Treatment Options for Pancreatic Cancer Patients
Alliance Creates Opportunity to Maximize the Strengths of Both Organizations for Patient Benefit Los Angeles, Calif. and Larkspur, Calif., January […]
READ MORE
Five-Year Pancreatic Cancer Survival Rate Increases to 12%
The one percentage point increase signifies important progress.
Meet Four Researchers Bringing Progress to Patients
Read stories and watch short videos about scientists making new discoveries every day.
Back in Person, PanCAN Scientific Summit Offers Data-sharing, Discussion and Progress
The PanCAN Scientific Summit allowed for data-sharing, discussion and collaboration.
PanCAN Announces Its Largest-ever Research and Research Grants Investment
PanCAN is investing nearly $25 million in conducting and funding research in 2022.
Recap of the Largest-Ever American Society of Clinical Oncology Meeting
Clinical trial results and PanCAN’s initiatives were highlighted at major meeting.
Statement From the Pancreatic Cancer Action Network (PanCAN) In Response To Results Of Cantargia’s Phase 1/2a Trial Of Nadunolimab
The Pancreatic Cancer Action Network (PanCAN) is pleased to hear about the promising results of Cantargia’s Phase 1/2a trial of […]
READ MORE
PanCAN Precision Promise – Learnings, Expanding the Trial and More
PanCAN President and CEO shares latest updates regarding PanCAN Precision Promise clinical trial.
Pancreatic Cancer Action Network Adaptive Clinical Trial Adds New Investigational Treatment and Additional Sites
Investigational Treatment From Novartis To Be Activated At Precision PromiseSM Clinical Trial Sites Across the Country, Including Five Additional Premier […]
READ MORE
1st Experimental Drug Tested in PanCAN Precision Promise Is Discontinued
Patients – and their safety – are at the center of every decision.
The Changing Clinical Trials Landscape
Clinical trials are testing new treatment approaches and becoming more innovative.
Five-Year Pancreatic Cancer Survival Rate Increases to 11%
The one percentage point increase signifies important progress.
Clinical Trials Bring New Treatments to Patients
In the fight against pancreatic cancer, clinical trials are critical.
2021 Year in Review: Progress in Research
Thanks to you, we’re making progress toward early detection and better treatments.
Two Pancreatic Cancer Clinical Trials Fail to Improve Overall Survival
Trials from ERYTECH Pharma and Rafael Pharmaceuticals did not meet primary goal.
PanCAN Scientific Summit Recap
PanCAN grantees, advisers, industry members and guests gathered to discuss research.
Virtual Conference Highlights Real, Exciting Progress
Conference featured exciting new results, robust discussion and a look to the future.
